Targeted Therapies in Oncology Welcomes Dr. Robert Ferris as Co-Physician Editor-In-Chief

Robert L. Ferris, MD, PhD

Robert L. Ferris, MD, PhD

Targeted Therapies in Oncology, an oncology publication that provides oncology professionals with cutting-edge research, data, and treatment strategies surrounding molecular and immune system targets, has appointed Robert L. Ferris, MD, PhD, as its co-physician editor-in-chief.

“We look forward to having Dr. Ferris joining theTargeted Therapies in Oncologyteam,” said Michael J. Hennessy Jr., president of MJH Associates Inc., parent company ofTargeted Oncology. ™ “His impeccable experience and contributions in the field of immunology and oncology will help improve our team’s ability to deliver unprecedented information and data to our audience.”

“We look forward to having Dr. Ferris joining theTargeted Therapies in Oncologyteam,” said Michael J. Hennessy Jr., president of MJH Associates Inc., parent company ofTargeted Oncology. ™ “His impeccable experience and contributions in the field of immunology and oncology will help improve our team’s ability to deliver unprecedented information and data to our audience.”

In this role, Dr. Ferris will work closely with the editorial team to promote major targeted therapy innovations and updates. He will also be joining Arjun V. Balar, M.D., as co-physician editor-in-chief of the publication. The addition of Dr. Ferris will allowTargeted Therapies in Oncologyto increase its frequency and begin publishing up to two issues every month. This new publishing schedule will begin in December 2018.

“I am delighted to assistTargeted Therapies in Oncologyin its mission to disseminate important and exciting advances in the rapidly emerging new treatments in cancer research and treatment,” said Ferris. “Targeted Therapies in Oncologyis truly a gem, and I look forward to helping it continue as a valuable resource for oncologists.”

Dr. Ferris is the director of the University of Pittsburgh Medical Center’s Hillman Cancer Center, the Hillman professor of oncology, associate vice chancellor for cancer research and co-director of the Tumor Microenvironment Center. His research primarily focuses on cellular immune mechanisms of natural killer cells, dendritic cells, and T-lymphocyte activation against head and neck cancer tumor antigens. His group also conducts research on mechanisms of tumor antigen processing and immunologic evasion used by head and neck cancer cells.

AboutTargeted Oncology™